- Home
- AMPL vs DYN Comparison
AMPL vs DYN Comparison
Compare AMPL & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMPL
- DYN
- Stock Information
- Founded
- AMPL 2012
- DYN 1984
- Country
- AMPL United States
- DYN United States
- Employees
- AMPL N/A
- DYN N/A
- Industry
- AMPL EDP Services
- DYN Medicinal Chemicals and Botanical Products
- Sector
- AMPL Technology
- DYN Health Care
- Exchange
- AMPL Nasdaq
- DYN Nasdaq
- Market Cap
- AMPL 1.5B
- DYN 1.3B
- IPO Year
- AMPL 2021
- DYN 2020
- Fundamental
- Price
- AMPL $12.48
- DYN $11.96
- Analyst Decision
- AMPL Buy
- DYN Strong Buy
- Analyst Count
- AMPL 10
- DYN 12
- Target Price
- AMPL $13.50
- DYN $47.00
- AVG Volume (30 Days)
- AMPL 1.8M
- DYN 2.5M
- Earning Date
- AMPL 05-07-2025
- DYN 05-08-2025
- Dividend Yield
- AMPL N/A
- DYN N/A
- EPS Growth
- AMPL N/A
- DYN N/A
- EPS
- AMPL N/A
- DYN N/A
- Revenue
- AMPL $306,601,000.00
- DYN N/A
- Revenue This Year
- AMPL $12.82
- DYN N/A
- Revenue Next Year
- AMPL $10.82
- DYN N/A
- P/E Ratio
- AMPL N/A
- DYN N/A
- Revenue Growth
- AMPL 8.56
- DYN N/A
- 52 Week Low
- AMPL $7.37
- DYN $6.36
- 52 Week High
- AMPL $14.88
- DYN $47.45
- Technical
- Relative Strength Index (RSI)
- AMPL 61.97
- DYN 55.03
- Support Level
- AMPL $11.78
- DYN $11.52
- Resistance Level
- AMPL $12.79
- DYN $12.34
- Average True Range (ATR)
- AMPL 0.53
- DYN 0.78
- MACD
- AMPL 0.04
- DYN -0.02
- Stochastic Oscillator
- AMPL 73.36
- DYN 42.47
About AMPL Amplitude Inc.
Amplitude Inc is a Software company that provides a Digital Analytics Platform that helps companies analyze their customer behavior within digital products. The Company delivers its application over the Internet as a subscription service using a software-as-a-service (SaaS) model and also it offers customer support related to initial implementation setup, ongoing support services, and application training. The company generates revenue primarily through selling subscriptions to the platform. The company derives a majority of its revenue from the United States.
About DYN Dyne Therapeutics Inc.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.